The Claim
Measurement of TBII or TSAb at the time of anti-thyroid drug discontinuation provides minimal additional predictive value for long-term remission in Graves' disease beyond the criterion of six months of euthyroidism on minimum maintenance therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Testing for TBII or TSAb antibodies when stopping thyroid medication does not improve the ability to predict whether Graves' disease will stay in remission, beyond knowing that the patient has been euthyroid for six months on low-dose medication.
See the scientific wording
The measurement of TBII or TSAb at the time of anti-thyroid drug discontinuation provides minimal additional predictive value for long-term remission in Graves' disease beyond the simple criterion of six months of euthyroidism on minimum maintenance therapy.
When the thyroid works normally for six months on a low dose of medicine, the immune system stops attacking the thyroid because the signals that kept it active fade away. This makes the disease stay gone even after the medicine is stopped, and checking for antibodies doesn't add useful information because the immune system has already quieted down.
What the research says
1 studyDoctors found that if a patient’s thyroid is working normally for six months on a very low dose of medicine, they’re likely to stay healthy even after stopping the medicine — and checking for certain antibodies didn’t help predict this much better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.